Tourette Syndrome - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Tourette Syndrome - Pipeline Review, H2 2019’, provides an overview of the Tourette Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome

- The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects

- The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Tourette Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Asarina Pharma AB

Catalyst Pharmaceuticals Inc

H. Lundbeck AS

KemPharm Inc

Neurocrine Biosciences Inc

SOM Biotech SL

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Asarina Pharma AB

Catalyst Pharmaceuticals Inc

H. Lundbeck AS

KemPharm Inc

Neurocrine Biosciences Inc

SOM Biotech SL

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tourette Syndrome - Overview

Tourette Syndrome - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tourette Syndrome - Overview

Tourette Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tourette Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tourette Syndrome - Companies Involved in Therapeutics Development

Asarina Pharma AB

Catalyst Pharmaceuticals Inc

H. Lundbeck AS

KemPharm Inc

Neurocrine Biosciences Inc

SOM Biotech SL

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Tourette Syndrome - Drug Profiles

(amfetamine + guanfacine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alpha-dihydrotetrabenazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevantolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deutetrabenazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol + palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ecopipam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepranolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THX-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valbenazine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tourette Syndrome - Dormant Projects

Tourette Syndrome - Discontinued Products

Tourette Syndrome - Product Development Milestones

Featured News & Press Releases

Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome

Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development

Dec 13, 2018: Neurocrine reports negative topline results from T-Force GOLD study

Oct 18, 2018: Abide Therapeutics starts Phase II trial of Tourette syndrome drug

Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

Apr 10, 2018: Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting

Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients

Feb 07, 2018: Abide Therapeutics to Participate in February 2018 Investor Conferences

Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

Nov 28, 2017: Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome

Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome

Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome

Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Tourette Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products ...

List of Tables

Number of Products under Development for Tourette Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Tourette Syndrome - Pipeline by Asarina Pharma AB, H2 2019

Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2 2019

Tourette Syndrome - Pipeline by H. Lundbeck AS, H2 2019

Tourette Syndrome - Pipeline by KemPharm Inc, H2 2019

Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H2 2019

Tourette Syndrome - Pipeline by SOM Biotech SL, H2 2019

Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019

Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H2 2019

Tourette Syndrome - Dormant Projects, H2 2019

Tourette Syndrome - Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Tourette Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products ...

List of Figures

Number of Products under Development for Tourette Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports